Skip to content
Home » Vaccines » RSV vaccine

RSV vaccine

COVID-19 rsv flu

CDC reports low COVID, RSV, flu vaccination rates

During the 2023-24 winter, the U.S. is facing increased risks of COVID-19, RSV, and influenza due to low vaccination rates. The CDC reports that only 21.4% of adults over 18 and 41.5% of those over 65 received the COVID-19 vaccine. Flu vaccination rates are better at 46.8% for adults and 74.1% for seniors. However, only 20.1% of seniors are vaccinated against RSV. Children’s vaccination rates have yet to be revealed.

rsv COVID flu tripledemic

Flu, COVID, RSV on the rise — beware the tripledemic

The USA, including California, faces a ‘tripledemic’ of seasonal flu, new COVID-19 variants, and respiratory syncytial virus (RSV). All three respiratory viruses, particularly harmful to seniors and children, can be prevented through vaccination. Despite this, many places are reporting low vaccination rates, especially among older people. The content highlights RSV’s severity and contagion, recent research into the virus, and the situation with the three diseases in California and other states.

respiratory syncytial virus

Respiratory syncytial virus, flu, and COVID-19 — the “tripledemic”

I rarely write about the respiratory syncytial virus (RSV), but the number of people infected by the virus, especially children, is leading to a fear of a tripledemic that includes RSV, the seasonal flu, and our constant nemesis, COVID-19. I guess this is the time I start writing more about the respiratory syncytial virus because everyone needs to be aware of this infectious disease.

This post will review what respiratory syncytial virus is, why it is so dangerous to children and seniors, and whether a vaccine is available.

Read More »Respiratory syncytial virus, flu, and COVID-19 — the “tripledemic”
rsv vaccine

RSV vaccine candidates are entering phase 3 trials — stopping a dangerous disease

A respiratory syncytial virus (RSV) vaccine has been a goal for researchers for a long time, given the serious outcomes of an RSV infection. According to the CDC, an RSV vaccine could dramatically reduce hospital and intensive-care admissions, especially for children and seniors.

A series of clinical trials tested a vaccine made from inactivated RSV in children in the 1960s. Unfortunately, the vaccine candidate worsened the disease in children when they were later naturally infected with RSV.

However, these new vaccines have shown good safety and effectiveness results in clinical trials. This article will review what RSV is and the list of vaccine candidates that are entering or are in phase 3 clinical trials.

Read More »RSV vaccine candidates are entering phase 3 trials — stopping a dangerous disease